Printer Friendly

Novo Nordisk receives EU marketing authorisation for Esperoct.

M2 EQUITYBITES-June 21, 2019-Novo Nordisk receives EU marketing authorisation for Esperoct

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Global pharmaceutical company Novo Nordisk A/S (CPH:NOVOB) said on Thursday that the European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents (aged 12 years or over) and adults with haemophilia A. This authorisation covers all 28 EU member states.

Esperoct, the brand name for turoctocog alfa pegol, N8-GP, is indicated for prophylaxis and on-demand treatment of bleeding, as well as for surgical procedures in adolescents and adults with haemophilia A (congenital factor VIII deficiency).

According to the company, the efficacy and safety evaluation was based on the results from the largest pre-registration clinical programme conducted in haemophilia A, with inclusion of 270 previously treated people (PTPs) with severe haemophilia A and more than five years of clinical exposure. This marketing authorisation follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), provided 26 April 2019.

Novo Nordisk expects to launch Esperoct in the first European countries during the second half of 2019.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 21, 2019
Words:198
Previous Article:Skanska announces sale of multi-family development in Washington D.C. for USD141m.
Next Article:AbbVie's board declares USD1.07 per share quarterly dividend.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters